Adequacy of Calcium and Phosphate Balance in Peritoneal Dialysis

Lopez-Hilker S. , Galceran T. , Chan U-L , Rapp N. , Martin K. , Slatopolsky E. Hypocalcaemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986; 78: 1097–102.

Lopez-Hilker S. , Dusso A. , Rapp N. , Martin K. , Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 259: 432–7.

Ritz E. , Matthias S. , Seidel A. , Reichel H. , Szabo A. , Horl W. Disturbed calcium metabolism in renal failure pathogenesis and therapeutic strategies. Kidney Int 1992; 42(Suppl 38): S37–42.

Hutchison A. , Whitehouse R. , Boulton H. Correlation of bone histology with parathyroid hormone, vitamin D, and radiology in end-stage renal disease. Kidneylnt 1993; 44: 1071–7.

Holick M. Vitamin D and the kidney. Kidneylnt 1987; 32: 912–29.

Lee D. , Brautbar N. , Kleeman C. Disorders of phosphorus metabolism. In: Bronner F. , Coburn J. , eds. Disorders of mineral metabolism: pathophysiology of calcium, phosphorus and magnesium. New York: Academic, 1981; 3: 283–421.

Blumenkrantz M. , Kopple J. , Moran J. , Coburn J. Metabolic balance studies and dietary protein requirements in patients undergoing CAPD. Kidney Int 1982; 21: 849–61.

Lindholm B. , Bergstrom J. Nutritional aspects of CAPD. In: Gokal R. , ed. Continuous ambulatory peritoneal dialysis. Edinburgh: Churchill Livingstone, 1986: 228–55.

Kumar R. Vitamin D and calcium transport. KidneyInt 1991; 40: 1177–89.

Nolph K. , Prowant B. , Serkes K. Multicenter evaluation of a new peritoneal dialysis solution with a high lactate and a low magnesium concentration. Perit Dial Bull 1983; 3: 63–5.

Bucciante G. , Biachi M. , Valenti G. Progress of renal osteodystrophy during CAPD. Clin Nephrol 1984; 6: 279–83.

Hercz G. , Coburn J. Prevention of phosphate retention and hyperphosphatemia in uremia. Kidney Int 1987; 32(Suppl 22): S215–20.

Delmez J. , Fallon M. , Bergfeld M. , Gearing B. , Dougan C. , Teitelbaum S. Continuous ambulatory peritoneal dialysis and bone. Kidney Int 1986; 30: 379–84.

Martis L. , Serkes K. , Nolph K. Calcium carbonate as a phosphate binder: is there a need to adjust peritoneal calcium concentrations for patients using calcium carbonate? Perit Dial Int 1989; 9: 325–8.

Ott S. Aluminum accumulation in individuals with normal renal function. Am J Kidney Dis 1985; 4: 297–301.

Joffe P. , Olsen F. , Heaf J. , Gammelgaard B. , Podenphant J. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis. Clin Nephrol 1989; 32(3): 133–8.

Salusky I. , Coburn J. , Foley J. , Nelson P. , Fine R. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminium levels after discontinuation of aluminium-containing gels in children receiving dialysis. J Pediatr 1986; 108: 767–70.

Slatopolsky E. , Weerts C. , Lopez-Hilker S. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. New Engl J Med 1986; 315: 157–61.

Stein H. , Yudis M. , Sirota R. Calcium carbonate as a phosphate binder. New Engl J Med 1987; 316: 109–10.

Sheikh M. , Maguire J. , Emmett M. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83: 66–73.

Ramirez J. , Emmett M. , White M. The absorption of dietary phosphorus and calcium in haemodialysis patients. Kidney Int 1986; 30: 753–9.

Ben Hamida F. , El Esper I. , Compagnon M. , Moriniere P. , Fournier A. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 1993; 63: 258–62.

Moriniere P. , Djerad M. , Boudailliez B. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Nephron 1992; 60: 6–11.

Caravaca F. , Santos I. , Cubero J. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992; 60: 423–7.

Brown A. , Finch J. , Lopez-Hilker S. New active analogues of vitamin D with low calcemic activity. Kidney Int 1990; 38(Suppl 29): 822–7.

Demontis R. , Westeel B. , Boudailliez B. One alpha hydroxyvitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3. Kidney Int 1988; 33(Suppl 24): S175–7.

Demontis R. , Reissi D. , Noel C. Indirect clinical evidence that one alpha hydroxyvitamin D3 increases plasma aluminum in hemodialyzed patients taking aluminum hydroxide. Kidney Int 1989; 31: 123–7.

Burnakowska-Heldin M. , Doyle T. , Eadie M. , Mayor G. 1,25(OH)2 vitamin D3 increases serum and tissue accumulation of aluminum in rats. J Lab Clin Invest 1986; 108: 96–102.

Morton A. , Hercz G. , Coburn J. Control of hyperphosphatemia in chronic renal failure. Semin Dial 1990; 3: 219–23.

Coburn J. Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int 1993; 43(Suppl 40): S92–100.

Cunningham J. , Beer J. , Coldwell R. , Noonan K. , Sawyer N. , Makin H. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992; 7(1): 63–8.

Slatopolsky E. , Weerts C. , Thielan J. , Horst R. , Harter H. , Martin K. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136–43.

Martin K. , Ballal H. , Domoto D. , Blalock S. , Weindel M. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 1992; 19: 540–5.

Bowers G. , Brassard C. , Sena F. Measurement of ionized calcium in serum with ion-selective electrodes: a mature technology that can meet the daily service needs. Clin Chem 1986; 32(8): 1437–47.

Parker A. , Nolph K. Magnesium and calcium transfer during continuous ambulatory peritoneal dialysis. Trans Am SocArtiflntern Organs 1980; 26: 194–6.

Kwong M. , Lee J. , Chan M. Transperitoneal calcium and magnesium transfer during an eight hour dialysis. Perit Dial Bull 1987; 7: 85–9.

Piraino B. , Bernardini J. , Holley J. , Johnston J. , Perlmutter J. , Martis L. Calcium mass transfer in peritoneal dialysis patients using 2.5 mEq/L calcium dialysate. Clin Nephrol 1992; 37(1): 48–51.

Hutchison A. , Merchant M. , Boulton H. , Hinchcliffe R. , Gokal R. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Perit Dial Int 1993; 13: 219–23.

Schiller L. , SantaAna C. , Sheikh M. , Emmett M. , Fordtran J. Effect of the timing of administration of calcium acetate on phosphorus binding. New Engl J Med 1989; 320: 1110–13.

Randall R. , Cohen M. , Spray C. , Rossmeisl E. Hypermagnesemia in renal failure. Etiology and toxic manifestations. Ann Intern Med 1964; 61: 73–88.

Guillot A. , Hood V. , Runge C. , Gennari F. The use of magnesium- containing phosphate binders in patients with end-stage renal disease on maintenance dialysis. Nephron 1982; 30: 114–17.

Jennings A. , Bodvarsson M. , Galicka-Piskorka G. , Diefendorf A. , Simon G. , Levey A. Use of magnesium hydroxide and low magnesium dialysate does not permit reduction of aluminum hydroxide during continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1986; 8: 192–5.

Parsons V. , Baldwin D. , Moniz C. , Marsden J. , Ball E. , Rifkin I. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders. Nephron 1993; 63: 379–83.

Schaefer K. , von Herrath D. , Asmus G. , Umlauf E. The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia. Clin Nephrol 1988; 30: 93–6.

Nebeker H. , Schneider H. , Coburn J. A non-aluminium containing phosphate binder: polyuronic acid. Kidney Int 1985; 27: 147.

Hutchison A. , Freemont A. , Boulton H. , Gokal R. Lowcalcium dialysis fluid and oral calcium carbonate in CAPD: a method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219–25.

Piraino B. , Bernardini J. , Perlmutter J. , Holley J. , Johnston J. 2.5 mEq/1 Ca dialysate and CaCO3 vs 3.5 mEq/l Ca dialysate and aluminum in PD patients. Perit Dial Int 1991; 11(Suppl 1): 208.

Hercz G. , Pei Y. , Manuel A. Aplastic osteodystrophy without aluminum staining in dialysis patients (Abstract). Kidney Int 1990; 37: 449.